Albiglutide in type 2 diabetes mellitus: evidence of little added value

Albiglutide (trade name Eperzan) was approved in March 2014 for use by adults with type 2 diabetes mellitus where diet and exercise do ...

Read more →

Daclatasvir for hepatitis C: added benefit not proven

The drug daclatasvir (trade name Daklinza) has been available since August 2014 for the treatment of adults with chronic hepatitis ...

Read more →

Sipuleucel-T in prostate cancer: additional benefit has not been established

Sipuleucel-T (Provenge) has been authorised since September 2014 for use by men with metastatic prostate cancer who have little or no ...

Read more →

IQWIG finds that vismodegib (Erivedge) provides no additional benefit for patients with basal cell carcinoma

[:content [\V \i \s \m \o \d \e \g \i \b \space \( \E \r \i \v \e \d \g \e \) \space \i \s \space \a \p \p \r \o \v \e \d \space \f \o \r \space \t \h \e \space \t \r \e \a \t \m \e \n \t \space \o \f \space \p \a \t \i \e \n \t \s \space \w \i \t \h \space \t \w \o \space \f \o \r \m \s \space \o \f \space \b \a \s \a \l \space \c \e \l \l \space \c \a \r \c \i \n \o \m \a \: \space \o \n \e \space \w \i \t \h \space \s \y \m \p \t \o \m \a \t \i \c \space \m \e \t \a \s \t \a \t \i \c " ..."]]
Read more →

BMS pulls diabetes drug from Germany in price fight

[:content [\1 \4 \space \D \e \c \e \m \b \e \r \space \2 \0 \1 \3 \space \- \space \B \M \S \space \& \space \A \s \t \r \a \Z \e \n \e \c \a \space \h \a \v \e \  \p \u \l \l \e \d \space \t \h \e \i \r \space \d \i \a \b \e \t \e \s \space \t \r \e \a \t \m \e \n \t \space \F \o \r \x \i \g \a \space \( \d \a \p \a \g \l \i \f \l \o \z \i \n \) \space \f \r \o \m \space \t \h \e \space \G \e \r \m \a \n \space \m \a \r \k \e \t \space \a \f \t \e \r \space \t \h \e \space \c \o \m \p \a \n \i \e \s " ..."]]
Read more →

Bayer’s Adempas (riociguat) approved for the treatment of two life-threatening forms of pulmonary hypertension in the EU

[:content [\3 \1 \space \M \a \r \c \h \space \2 \0 \1 \4 \space \- \  " ..."]]
Read more →

Ruxolitinib for myelofibrosis: indication of considerable added benefit

Ruxolitinib (trade name: Jakavi) has been approved since August 2012 for the treatment of adults with myelofibrosis. In an early ...

Read more →

German insurers win discounts on Gilead's Sovaldi

U.S. biotechnology company Gilead has conceded its first discounts in Germany on its key hepatitis C drugs Sovaldi and Harvoni, German business weekly WirtschaftsWoche ...

Read more →

Enzalutamide: indication of major added benefit for over 75-year-olds

Enzalutamide (trade name: Xtandi) has been approved since December 2014 for men who have metastatic prostate cancer that is not ...

Read more →

Dabrafenib in melanoma: added benefit not proven

[:content [\D \a \b \r \a \f \e \n \i \b \space \m \e \s \y \l \a \t \e \space \( \T \a \f \i \n \l \a \r \) \space \h \a \s \space \b \e \e \n \space \a \p \p \r \o \v \e \d \space \i \n \space \G \e \r \m \a \n \y \space \s \i \n \c \e \space \A \u \g \u \s \t \space \2 \0 \1 \3 \space \f \o \r \space \t \h \e \space \t \r \e \a \t \m \e \n \t \space \o \f \space \p \a \t \i \e \n \t \s \space \w \i \t \h \  \a \d \v \a \n \c \e \d \space \m \e \l \a \n \o \m \a \. \space \I \n \space \a \n " ..."]]
Read more →

Radium Ra223 dichloride in prostate cancer: major added benefit for certain patients

[:content [\1 \space \A \p \r \i \l \space \2 \0 \1 \4 \space \- \  \R \a \d \i \u \m \space \R \a \2 \2 \3 \space \d \i \c \h \l \o \r \i \d \e \space \( \X \o \f \i \g \o \) \space \h \a \s \space \b \e \e \n \space \a \p \p \r \o \v \e \d \space \s \i \n \c \e \space \N \o \v \e \m \b \e \r \space \2 \0 \1 \3 \space \f \o \r \space \m \e \n \space \w \i \t \h \space \a \d \v \a \n \c \e \d \space \p \r \o \s \t \a \t \e \space \c \a \n \c \e \r \, \space \i \n " ..."]]
Read more →

Clinical studies: Broad definition of commercially confidential information endangers transparency

In April 2014 the EU Parliament and Council commissioned the European Medicines Agency (EMA) to establish a publicly accessible database ...

Read more →

Eisai resubmits Fycompa to German Federal Joint Committee for additional benefit assessment

Eisai announced today that its German sales company Eisai GmbH has resubmitted its first-in-class anti-epilepsy drug Fycompa (perampanel) to the German Federal ...

Read more →

Added benefit of saxagliptin hydrochloride as monotherapy is not proven

[:content [\2 \space \D \e \c \e \m \b \e \r \space \2 \0 \1 \3 \space \- \space \S \a \x \a \g \l \i \p \t \i \n \space \h \y \d \r \o \c \h \l \o \r \i \d \e \space \( \O \n \g \l \y \z \a \) \space \h \a \s \space \b \e \e \n \space \a \p \p \r \o \v \e \d \space \a \l \s \o \space \a \s \space \m \o \n \o \t \h \e \r \a \p \y \space \i \n \space \G \e \r \m \a \n \y \space \s \i \n \c \e \space \J \u \l \y \space \2 \0 \1 \3 \space \f \o \r \space \c \e \r \t \a \i \n " ..."]]
Read more →

IQWiG: internationally health economic evaluations are a fixed component of reimbursement decisions

Internationally health economic evaluations (HEEs) form a legally regulated fixed component in health-care decisions. This applies particularly to the drug ...

Read more →